Metformin has been explored as an adjuvant therapy for HCC, as low doses promote hepatoma cell senescence by activating the AMPK pathway and inhibiting SIRT1, offering a strategy to reduce tumor growth (Yi et al., 2013; Meng et al., 2023). This evidence concerns the gene SIRT1 and hepatocellular carcinoma.